drugset / Trial / NCT04074421
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
Phase 4
Unknown
240 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
First Affiliated Hospital of Wenzhou Medical University · collabPeking Union Medical College Hospital · collabRenJi Hospital · collabSir Run Run Shaw Hospital · collabThe Central Hospital of Lishui City · collabThe First Affiliated Hospital of Zhejiang Chinese Medical University · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on different symptoms and quality of life. High-throughput sequencing combined with real-time quantitative PCR will be used to comprehensively analyze the effects of different drugs on intestinal flora. The study has important guiding significance for the treatment of patients with IBS-D.
Timeline
- Start
- 2020-05-10
- Primary completion
- 2022-06
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bacillus subtilis | Vaccine | — | — |
| Comparator | Enterococcus faecium | Unknown | 500 mg | — |
| Comparator | Rifaximin | Other / unclassified | 400 mg | — |